Adverse Reaction to Drug Clinical Trial
Official title:
The Efficacy and Safety of Sertraline in Maintenance Hemodialysis Patients With Depression: a Randomized Controlled Study
Depression is a common mental disorder in patients undergoing maintenance hemodialysis (MHD), which increases the risk of cardiovascular events, hospitalization rates, and mortality, but has not received enough attention from patients and medical staff. Sertraline is a selective serotonin reuptake inhibitor with fewer adverse reactions and higher safety compared to other antidepressants. This study aims to investigate the efficacy and safety of sertraline in patients undergoing MHD with depression. This study used a randomized controlled design and evaluated the depression status of the patients using the Hamilton Depression Scale (HAMD). MHD patients with comorbid depression were recruited and divided into the treatment group and the control group. The treatment group received sertraline for antidepressant therapy, while the control group did not receive any antidepressant medication. To investigate the efficacy and safety of sertraline before and after intervention.
The HAMD, the Medication Adherence Report Scale-5 (MARS-5), the Mini Nutritional Assessment short-form (MNA-SF) and the Kidney Disease Quality of Life-36 (KDQOL-36) scales were used to evaluate changes in depression status, quality of life, medication adherence and nutritional status before and after the intervention. Clinical and laboratory indicators were collected before and after the intervention. Adverse reactions during the intervention were also recorded. The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication. In the control group, no antidepressant treatment was given. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01430702 -
Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults
|
N/A | |
| Active, not recruiting |
NCT01237275 -
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
|
N/A | |
| Terminated |
NCT02296840 -
Post-operative Pain Control After Pediatric Adenotonsillectomy
|
Phase 4 | |
| Terminated |
NCT01600677 -
Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions
|
N/A | |
| Recruiting |
NCT02353455 -
Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity
|
||
| Completed |
NCT02012712 -
Personal Health Records and Elder Medication Use Quality
|
N/A | |
| Completed |
NCT02609919 -
Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age
|
||
| Recruiting |
NCT00817375 -
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
|
N/A | |
| Active, not recruiting |
NCT00935246 -
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
|
N/A | |
| Completed |
NCT04226443 -
The Use of Midazolam and Remifentanil During Dialysis Access Procedures
|
N/A | |
| Recruiting |
NCT02520570 -
Post-market Safety Reassessment of Ulinastatin for Injection
|
||
| Completed |
NCT01621373 -
Exploratory Propofol Dose Finding Study In Neonates
|
Phase 2 | |
| Completed |
NCT02447679 -
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
|
Phase 2 | |
| Recruiting |
NCT05645302 -
Intensive Monitoring Scheme of Lidocaine Cataplasms
|
||
| Enrolling by invitation |
NCT01830257 -
Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)
|
Phase 4 | |
| Recruiting |
NCT01354197 -
The Thai Surgical Intensive Care Study (Thai-SICU Study)
|
N/A | |
| Recruiting |
NCT04655794 -
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
|